Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMPT study of Tecfidera in treatment-naive relapsing-remitting multiple sclerosis
2015-000303-21Phase 4Terminated
- Sponsor
- Biogen
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Tecfidera with Placebo (2 arms). Primary endpoint: Mean number of cumulative combined unique active lesions from week 4 to week 24. Started Apr 2015; status: terminated.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2015-000303-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000303-21.